CLEO is pleased to announce the commencement of technology transfer activities supporting the development of its simple blood test for the early and accurate detection of Ovarian Cancer. This marks the completion of a critical milestone in the manufacturing pathway for CLEO to deliver its commercially available, FDA-compliant diagnostic test kit.

CLEO has expanded its ovarian cancer Australian trial to include Siles Health network of 13 clinics across Melbourne and regional Victoria. Siles Health is a prominent women’s health and ultrasound specialist, with Associate Professor Charles Siles, acting as Principal Investigator.

CLEO has expanded its ovarian cancer Australian trial with the inclusion of the Royal Women’s Hospital as a participating site.